identification of an existing japanese pancreatitis drug , nafamostat , which is expected to prevent the transmission of new coronavirus infection
identification of an existing japanese pancreatitis drug , nafamostat , which is expected to prevent the transmission of new coronavirus infection
the university of tokyo plans to launch clinical trials in april 2020 in order to evaluate the effectiveness of these two drugs for treating covid-19.", "both nafamostat and camostat were developed in japan as treatments for pancreatitis and some other diseases.", "according to the new research, nafamostat can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus sars-cov-2.", "nafamostat mesylate (brand name: fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (sars-cov-2) uses to spread and cause disease (covid-19)."


































)